It's time to say goodbye to ineffective and costly cancer treatments. Japanese scientists have found unique genetic alterations that could indicate whether expensive immune checkpoint inhibitors would be effective for a particular patient.
Programmed-death ligand 1 (PD-L1) is a protein that tells the immune system not to kill a particular cell. Publishing in Nature, a recent study reports that genetic alterations affecting a part of the PD-L1 gene increases the production of the protein, allowing cancer cells to escape detection by the immune system.
Japanese scientists have found unique genetic alterations that could indicate whether expensive immune checkpoint inhibitors would be effective for a particular patient. Publishing in Nature, the study reports that genetic alterations affecting a part of the PD-L1 gene increases the production of the protein, allowing cancer cells to escape detection by the immune system.
Credit: Kyoto University
"This is the first study to illustrate that a structural abnormality in the 3' untranslated region of the PD-L1 gene causes an abnormally high production of PD-L1 protein, consequently aiding cancer immune escape," says one of the lead authors, Keisuke Kataoka, at Kyoto University. "Our study suggests that whether or not a cancer has this particular abnormality could be a good indicator of its response to immune checkpoint inhibitor drugs."
Antibodies that target PD-L1 or its receptor PD-1 have shown remarkable therapeutic effects for many cancer patients, sometimes even for those who are terminally ill. Treatment using such antibodies is extremely expensive, however, and oncologists are keen to find a biomarker that can predict the effectiveness of these drugs for individual patients.
"We identified PD-L1 structural alterations affecting the 3' untranslated region of the PD-L1 gene in 27% of patients with adult T-cell leukemia/lymphoma by analyzing next-generation sequencing data," explains senior author Seishi Ogawa.
Prompted by this initial finding, the team searched for similar structural alterations in sequencing data from a total of 10,210 samples deposited in the Cancer Genome Atlas.
"Through this analysis, we found that such abnormalities were found in many common cancer types, including malignant lymphoma, as well as stomach and cervical cancers. We also generated human and mouse cells having a similar structural alteration using the CRISPR-Cas9 genome editing system, and confirmed that these cells actually showed an elevated expression of PD-L1 protein and were able to escape the immune attack." says Ogawa.
"To test the importance of such structural alteration as a genetic marker, a phase two clinical trial is ongoing at Kagoshima University and other institutions," adds Ogawa. "Once we confirm the significance of these genetic alterations, it'll be a game-changer for immunotherapy in cancer."
The paper "Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers" appeared May 23, 2016 in Nature, with doi: 10.1038/nature18294
Kyoto University is one of Japan and Asia's premier research institutions, founded in 1897 and responsible for producing numerous Nobel laureates and winners of other prestigious international prizes. A broad curriculum across the arts and sciences at both undergraduate and graduate levels is complemented by numerous research centers, as well as facilities and offices around Japan and the world. For more information please see: http://www.
Anna Ikarashi | EurekAlert!
Collagen nanofibrils in mammalian tissues get stronger with exercise
14.12.2018 | University of Illinois College of Engineering
New discoveries predict ability to forecast dementia from single molecule
12.12.2018 | UT Southwestern Medical Center
The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.
Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...
What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...
A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.
Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...
Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...
12.12.2018 | Event News
10.12.2018 | Event News
06.12.2018 | Event News
14.12.2018 | Power and Electrical Engineering
14.12.2018 | Physics and Astronomy
14.12.2018 | Physics and Astronomy